Advancing therapeutic candidates
Prepare for the clinic with an expert development partner
When you have a promising drug candidate, every decision is vital to keeping development on track. Forging ahead with the right partner can help you navigate the landscape efficiently and progress to the clinic with a product that is safe and effective.
With more than two decades of experience in guiding partners through preclinical development, TriLink® provides expert support and quality resources to bring your candidate therapeutic construct one step closer to market. We leverage a complete portfolio of manufacturing services, decades of expertise in designing and synthesizing complex constructs, and a comprehensive catalog of GMP-grade reagents to create personalized solutions for our partners.
From process development to scale-up and testing, our offerings ensure your mRNA-based therapeutic candidates are ready to reach their full clinical potential.
Simplify your pre-clinical development with our scalable processes and customizable capabilities
TriLink enables you to focus on demands at the preclinical stage while staying prepared for the steps ahead. With protocols in place for fully scalable and customizable manufacturing of RUO and GMP-grade materials, we provide the ease of a single development partner to swiftly move your project forward.
High-quality plasmid DNA
Phase-appropriate, high-quality plasmid DNA templates to support your mRNA therapeutic and vaccine programs.
Discovery mRNA synthesis
With TriLink, you can leverage our optimized in vitro transcription and purification processes to help meet your unique needs.
Our expert analytical services team also offers construct-specific assays and method development.
Ensure quality with industry-leading mRNA therapy materials & services
TriLink provides development partners with a reliable supply of high-purity, single-lot, GMP-grade modified NTPs and cap analogs. Our capabilities at every manufacturing grade set your product up for later success, ensuring a smooth transition into GMP manufacturing when it’s time to move to clinical trials. The TriLink Quality System is ISO 9001:2015 certified and meets ICH Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients, Section 19, APIs for use in clinical trials.
Our pre-designed, stocked mRNAs resemble fully processed, capped, and polyadenylated mRNAs ready for translation.
Co-transcriptional capping with CleanCap® analogs overcomes the limitations of legacy capping methods, helping you bring your mRNA vaccine or therapeutic to market faster.
Modified nucleoside triphosphates
Our modified NTPs are used in vaccine and therapeutic programs worldwide and continue to fuel the development of novel therapeutics.